Suppr超能文献

新型抗肿瘤药物卡贝替莫的作用机制

Mechanism of action of a new antitumor agent, carbetimer.

作者信息

Ardalan B, Paget G E

出版信息

Cancer Res. 1986 Nov;46(11):5473-6.

PMID:3756894
Abstract

Carbetimer, an intermediate molecular-weight-derivatized copolymer of maleic anhydride and ethylene, has been shown to possess significant antineoplastic activity in the stem cell assay. We have examined the antitumor activity of carbetimer in vivo and in vitro against HM5-Carb/S and M21, both primary human melanoma cell lines sensitive and resistant to carbetimer, respectively. The mechanism of action of carbetimer in HM5-Carb/S has been determined. Mice bearing palpable sensitive tumors were treated with 10% lethal doses of carbetimer (1500 mg/kg i.p.). The tumor nucleotide profile was determined 4 hours later. Uridine and cytidine nucleoside triphosphates were reduced by 36.6 and 58.2%, respectively. In a similar experiment using carbetimer-resistant tumor, there was no change in the tumor pool sizes of uridine and cytidine nucleoside triphosphate pools in carbetimer- or saline-treated animals. Following 24-h exposure of the cells to 1000 microM concentration of carbetimer, the carbetimer-sensitive cells were pulsed with [14C]uridine, cytidine, or thymidine for 30 min. Pyrimidine nucleotides, in particular triphosphates, were reduced significantly as compared to the saline-treated control. Similar treatment of carbetimer-resistant cells resulted in no change in the pool sizes of the nucleotides. [14C]Bicarbonate flux studies demonstrated that [14C]CO2 conversion into UMP and CMP was increased 200 and 140% of control in the carbetimer-sensitive cells treated with 1000 microM carbetimer; however, a similar treatment of the resistant cells showed no change in the pool sizes of the nucleotide. Examination of pyrimidine salvage enzymes demonstrated that, in the sensitive cells, carbetimer treatment reduced the specific activity of uridine, cytidine, and thymidine kinase by 46, 37, and 60%. In a similar study using resistant cells, the specific activities were reduced 7 and 0%, respectively. In the restitution studies coincubation of carbetimer-sensitive cells with carbetimer and uridine resulted in essentially the reversal of carbetimer cytotoxicity. Thus, carbetimer inhibits the growth of the sensitive cells by inhibiting the uptake and metabolism of performed nucleosides both in vivo and in vitro.

摘要

卡贝替莫是一种马来酸酐与乙烯的中等分子量衍生共聚物,在干细胞试验中已显示出显著的抗肿瘤活性。我们研究了卡贝替莫在体内和体外对HM5-Carb/S和M21这两种人原发性黑色素瘤细胞系的抗肿瘤活性,这两种细胞系分别对卡贝替莫敏感和耐药。已确定卡贝替莫在HM5-Carb/S中的作用机制。对可触及敏感肿瘤的小鼠给予10%致死剂量的卡贝替莫(1500毫克/千克腹腔注射)。4小时后测定肿瘤核苷酸谱。尿苷和胞苷三磷酸分别减少了36.6%和58.2%。在使用耐药肿瘤的类似实验中,卡贝替莫或生理盐水处理的动物中,尿苷和胞苷三磷酸池的肿瘤池大小没有变化。将细胞暴露于1000微摩尔浓度的卡贝替莫24小时后,对卡贝替莫敏感的细胞用[14C]尿苷、胞苷或胸苷脉冲标记30分钟。与生理盐水处理的对照相比,嘧啶核苷酸,特别是三磷酸,显著减少。对卡贝替莫耐药细胞进行类似处理,核苷酸池大小没有变化。[14C]碳酸氢盐通量研究表明,在用1000微摩尔卡贝替莫处理的卡贝替莫敏感细胞中,[14C]二氧化碳转化为尿苷一磷酸和胞苷一磷酸增加到对照的200%和140%;然而,对耐药细胞进行类似处理,核苷酸池大小没有变化。对嘧啶补救酶的检测表明,在敏感细胞中,卡贝替莫处理使尿苷、胞苷和胸苷激酶的比活性分别降低了46%、37%和60%。在使用耐药细胞的类似研究中,比活性分别降低了7%和0%。在恢复研究中,将卡贝替莫敏感细胞与卡贝替莫和尿苷共同孵育,基本上逆转了卡贝替莫的细胞毒性。因此,卡贝替莫通过在体内和体外抑制已有的核苷的摄取和代谢来抑制敏感细胞的生长。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验